PMID- 9485029
OWN - NLM
STAT- MEDLINE
DCOM- 19980319
LR  - 20171213
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 58
IP  - 4
DP  - 1998 Feb 15
TI  - HLA class I antigen and transporter associated with antigen processing (TAP1 and 
      TAP2) down-regulation in high-grade primary breast carcinoma lesions.
PG  - 737-42
AB  - Five specimens of normal mammary tissue and 53 primary breast carcinoma lesions 
      were tested for expression of HLA antigens and components of the 
      antigen-processing machinery by immunohistochemical staining. The expression of 
      transporter associated with antigen processing (TAP) 1, TAP2, and HLA class I 
      antigens in breast carcinoma lesions was significantly associated with tumor 
      grading. Like normal mammary tissue, the 16 low-grade (G1) breast carcinoma 
      lesions showed strong staining for TAP1, TAP2, and HLA class I antigens. In 
      contrast, only 12 (32%) of 37 high-grade (G2 and G3) breast carcinoma lesions 
      displayed the normal staining pattern. In 14 (38%) of 37 high-grade lesions, HLA 
      class I antigen down-regulation was observed without loss of low molecular mass 
      polypeptide and/or TAP staining. Congruent down-regulation of HLA class I antigen 
      and TAP1 or TAP2 was found in 8 (22%) of 37 high-grade lesions. Complete loss of 
      HLA class I antigens, TAP1, and TAP2 was observed in 3 (8%) of 37 high-grade 
      lesions. No lesion was negative for TAP1 and/or TAP2 staining while positive for 
      HLA class I antigen staining. These data demonstrate an association of HLA class 
      I antigen and TAP down-regulation with tumor progression in breast carcinoma. 
      This association suggests that loss of HLA and/or TAP may represent an escape 
      from the host's immune pressure or may reflect the accumulation of abnormalities 
      associated with neoplastic progression. This accumulation of defects in antigen 
      processing and presentation may in turn be responsible for reduced recognition of 
      malignant cells by putative clinically relevant tumor-specific T cells.
FAU - Vitale, M
AU  - Vitale M
AD  - Department of Biomedical Sciences and Biotechnologies, University of Brescia, 
      Italy.
FAU - Rezzani, R
AU  - Rezzani R
FAU - Rodella, L
AU  - Rodella L
FAU - Zauli, G
AU  - Zauli G
FAU - Grigolato, P
AU  - Grigolato P
FAU - Cadei, M
AU  - Cadei M
FAU - Hicklin, D J
AU  - Hicklin DJ
FAU - Ferrone, S
AU  - Ferrone S
LA  - eng
GR  - CA67108/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - ATP-Binding Cassette Transporters/*metabolism
MH  - *Antigen Presentation
MH  - Breast Neoplasms/*immunology/metabolism
MH  - Down-Regulation
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Humans
EDAT- 1998/03/04 00:00
MHDA- 1998/03/04 00:01
CRDT- 1998/03/04 00:00
PHST- 1998/03/04 00:00 [pubmed]
PHST- 1998/03/04 00:01 [medline]
PHST- 1998/03/04 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1998 Feb 15;58(4):737-42.